NCT01286935View on ClinicalTrials.gov

18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD

PHASE3CompletedINTERVENTIONAL
Enrollment

544

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

April 30, 2010

Study Completion Date

August 31, 2010

Conditions
Parkinson's Disease
Interventions
DRUG

Safinamide

DRUG

Safinamide

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Newron Pharmaceuticals SPA

INDUSTRY

NCT01286935 - 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PD | Biotech Hunter | Biotech Hunter